Prospective comparison of two treatment modalities in benign prostate hyperplasia: Alpha-blocker alone vs. alpha-blocker plus anticholinergic combination;Benign prostat hiperplazisi olgularında i̇ki tedavi modalitesinin prospektif karşılaştırılması: Tek başına alfa bloker ile alfa bloker ve antikolinerjik kombinasyon tedavisi

Turkiye Klinikleri Journal of Medical Sciences

Volumn 30, Issue 2, 2010, Pages 539-543

  Aldemir, Mustafa ^a   Aǧras, Koray ^a   Dehni, Deniz ^a   Kayigil, Önder ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Drug therapy; Prostatic hyperplasia

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; TOLTERODINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MALE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; XEROSTOMIA;

EID: 77952920622     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: 10.5336/medsci.2008-8467     Document Type: Article

References (23)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338(8765):469-71.
2. Mardy D. Eckhardt MD, van Venrooij GEPM, Boon TA. Urethral resistance factor (URA) versus Schäfer's obstruction grade and abramsgriffiths (AG) number in the diagnosis of obstructive benign prostatic hyperplasia Neurourol Urodyn 2001;20(2):175-85.
3. International Continence Society Benign Prostatic Hyperplasia Study: the botherosomeness of urinary symptoms. J Urol 1997;157(3):885-9.
4. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001;166(2):550-2.
5. Knutson T, Schäfer W, Fall M, Pettersson S, Dahlstrand C. Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting?--A four-year follow-up study. Scand J Urol Nephrol 2001;35(6):463-9.
6. Greenland JE, Brading AF. The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 2001;165(1):245-8.
7. Harrison SC, Hunnam GR, Farman P, Ferguson DR, Doyle PT. Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 1987;60(6):519-22.
8. Mirone V, Imbimbo C, Sessa G, Palmieri A, Longo N, Granata AM, et al. Correlation between detrusor collagen content and urinary symptoms in patients with prostatic obstruction. J Urol 2004;172(4 Pt 1):1386-9.
9. Seki N, Karim OM, Mostwin JL. Changes in electrical properties of guinea pig smooth muscle membrane by experimental bladder outflow obstruction. Am J Physiol 1992;262(5 Pt 2):F885-91.
10. Stoevelaar HJ, Van de Beek C, Casparie AF, McDonnell J, Nijs HG. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference? J Urol 1999;161(1):133-8.
11. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93(3):303-10.
12. Goepel M, Wittmann A, Rübben H, Michel MC. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 1997;25(3):199-206.
13. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94(6):817-20.
14. Schulman CC. Long-term aspects of medical treatment of BPH. Eur Urol 2001;40(Suppl 3):8-12.
15. Rosier PF, de la Rosette JJ, Wijkstra H, Van Kerrebroeck PE, Debruyne FM. Is detrusor instability in elderly males related to the grade of obstruction? Neurourol Urodyn 1995;14(6): 625-33.
16. Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol 1994;73(2): 117-23.
17. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol 1996;156(5):1662-7.
18. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174(6):2273-5.
19. Çevik I, Özveri H, Yücel S, Türkeri L, Akdaş A. [Medical treatment of lower urinary tract symptoms due to benign prostatic hyperplasia]. Turkiye Klinikleri J Med Sci 2001;21(3): 223-8.
20. Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, et al. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007;120(5):370-4.
21. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169(6):2253-6.
22. Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008;101(7):847-52.
23. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol 2003;43(1):1-5.